Author contribution
ABM
LY contributed to the trial design and wrote this report. ABM contributed to the data analysis and co-wrote this report. AV contributed to the trial operation overview and clinical study report (CSR). SP contributed to the clinical trial operations, data review, and analysis. ST contributed to the trial design, quality assurance of clinical trial process, and data interpretation. NA oversighted the whole clinic trial process. GA and VK were the principal investigators, conducted the clinical trial, and reviewed the manuscript. RST developed the proprietary manufacturing process for β-nicotinamide nucleotide (NMN) that made it possible to provide NMN as the investigational product of this trial. ZGL was responsible for the development of analytical methods for the quality control of NMN and the production of NMN under cGMP that made it possible to provide NMN as the investigational product for this trial.